Cagrilintide and semaglutide are not two versions of the same idea. They come from different hormone families and act at different receptors: cagrilintide is a long-acting amylin analog acting at calcitonin and amylin receptor complexes, while semaglutide is an acylated GLP-1 analog acting at the GLP-1 receptor. That is why the literature usually treats them as complementary rather than competing tools — the pairing studied under the name CagriSema exists precisely because the two pathways are separate. In a cagrilintide vs semaglutide comparison, the useful question is which satiation signalling pathway your model is built to read.
Both are supplied as lyophilized powder with lot-matched HPLC certificates: cagrilintide in 5 and 10 mg sizes and semaglutide in 5, 10, 20, 30 and 50 mg sizes, both listed under GLP-1 and incretin peptides. Both are research chemicals for laboratory use only, not medicines and not for human or veterinary use.
Cagrilintide vs semaglutide at a glance
| Attribute | Cagrilintide | Semaglutide |
|---|---|---|
| Hormone family | Amylin (islet amyloid polypeptide), a beta-cell hormone | Incretin (GLP-1), an intestinal L-cell hormone |
| Class | Acylated long-acting amylin analog | Acylated GLP-1 receptor agonist analog |
| Receptor targets studied | Calcitonin receptor and AMY1–AMY3 amylin receptor complexes | GLP-1 receptor |
| CAS number | 1415456-99-3 | 910463-68-2 |
| Molecular formula | C194H309N55O59S2 | C187H291N45O59 |
| Molecular weight | 4409.07 g/mol | 4113.58 g/mol |
| Structural notes | Amylin backbone with anti-fibrillation substitutions, an intramolecular disulfide and a lipid side chain | GLP-1(7-37) backbone, Aib at position 2, Lys26 gamma-Glu-(AEEA)2-C18 diacid |
| Distinctive handling risk | Aggregation chemistry of the amylin family; disulfide integrity | Lipophilic acyl chain; surface adsorption at high concentration |
| Typical research question | Satiation signalling, gastric emptying, area postrema circuitry | GLP-1 receptor pharmacology, islet secretion, food-intake models |
| Role in combination work | The amylin arm of amylin-plus-incretin study designs | The incretin arm of the same designs |
| Research sizes stocked | 5, 10 mg | 5, 10, 20, 30, 50 mg |
| Purity | ≥99% HPLC, lot-matched COA | ≥99% HPLC, lot-matched COA |
Two different hormones, not two versions of one
Native amylin is a 37-residue peptide co-secreted with insulin from pancreatic beta cells. It signals through complexes formed when the calcitonin receptor associates with receptor-activity-modifying proteins, producing the AMY1, AMY2 and AMY3 receptor phenotypes, and the published work associates it with satiation and slowed gastric emptying. Human amylin is notoriously awkward to work with because it aggregates into amyloid fibrils in solution, which is why native material is a poor benchtop reagent. Cagrilintide addresses both problems at once: sequence substitutions that suppress fibril formation and a lipid side chain that supports reversible albumin binding and a long working window. The full structural picture is in what is cagrilintide.
Semaglutide comes from the opposite end of the gut–islet axis. Its backbone is GLP-1(7-37), the incretin released after nutrient intake, stabilised by an Aib substitution against dipeptidyl peptidase-4 and acylated with a C18 diacid. It engages one receptor, the GLP-1 receptor, and it is the conventional reference agonist for that receptor in comparative panels.
Receptor pharmacology and why the pathways combine
The mechanistic reason these two molecules appear together in the literature is that their central targets overlap anatomically without overlapping pharmacologically. Amylin receptor signalling has been mapped prominently to the area postrema and adjacent hindbrain nuclei; GLP-1 receptor signalling has been described in overlapping hindbrain regions and in hypothalamic circuits. Because the receptors differ but the circuits converge, combining an amylin analog with an incretin agonist is a test of whether two independent satiation inputs are additive, synergistic or redundant. That is the explicit premise of the pairing discussed in our CagriSema and amylin analogs briefing, and it is the reason a fixed combination format such as semaglutide with cagrilintide exists as a research article at all.
Designing an amylin-versus-incretin comparison
- Confirm receptor expression: an AMY receptor phenotype requires both the calcitonin receptor and the relevant RAMP, so a cell line expressing calcitonin receptor alone is not an amylin receptor system.
- Use molar units. At 4409.07 and 4113.58 g/mol the two differ by about 7%, enough to bias a matched-mass comparison.
- Run each molecule alone before running them together; a combination arm without both mono-arms cannot distinguish additivity from redundancy.
- Where gastric emptying is the readout, plan for the fact that both pathways influence it, so the combination arm needs a longer observation window than either alone.
- For an amylin comparator with a shorter working window, pramlintide is the conventional short-acting reference.
What the research literature has examined
Cagrilintide's published record concentrates on the calcitonin receptor and its RAMP partners, on satiation pathways in the area postrema and hypothalamus, on gastric emptying endpoints in animal models, and on combination work with incretin agonists. Because native amylin aggregates so readily, a large part of the analog literature is chemistry rather than pharmacology: whether the anti-fibrillation substitutions preserve receptor activity, and how the lipid side chain changes distribution.
Semaglutide's record is deeper and differently shaped: GLP-1 receptor binding and cyclic-AMP kinetics in transfected lines, beta-arrestin recruitment and internalisation, insulin secretion in isolated islets and beta-cell lines, and rodent food-intake and body-composition work. Human trial data exist for approved pharmaceutical products containing semaglutide, and for investigational products containing cagrilintide; those studies describe regulated articles given under medical supervision, not research-grade peptide. Both compounds are surveyed alongside their alternatives in the weight-loss peptide research overview.
Which to select for which research question
- Amylin receptor pharmacology, RAMP-dependent signalling, calcitonin receptor work — cagrilintide. Semaglutide is inert at these receptors.
- GLP-1 receptor pharmacology, incretin potency panels — semaglutide. Cagrilintide contributes nothing at the GLP-1 receptor.
- Gastric emptying and satiation circuitry — both, run as separate arms; the two pathways influence overlapping endpoints through different receptors.
- Testing additivity of independent satiation signals — both plus a combination arm, ideally with a fixed-ratio format so the comparison is reproducible.
- Amyloid and peptide-aggregation chemistry — cagrilintide, as the engineered contrast to native amylin's fibrillation behaviour.
- Adding a second incretin receptor rather than a second hormone family — see semaglutide vs tirzepatide.
Handling, solubility and storage differences
Both are lyophilized powders stored at −20 °C, sealed and protected from light and moisture, and held at 2–8 °C once reconstituted, protected from light and used within the study window. General principles are set out in how to store peptides.
The differences are chemical. Cagrilintide carries an intramolecular disulfide, so reducing agents in a buffer will compromise it, and it belongs to a peptide family with well-documented aggregation behaviour — prepare solutions freshly, inspect concentrated stocks visually before use, and avoid vortexing, which introduces the shear and air interface that nucleate aggregation. Dilute buffers rather than plain water are common where assay pH matters. Semaglutide's issue is different: its C18 acyl chain makes it lipophilic enough to adsorb to standard plastics at low concentrations, so low-binding tubes and plates are the usual mitigation. Neither molecule tolerates repeated freeze–thaw exposure well, and aliquoting after reconstitution is the standard answer for both.
A worked concentration for the smaller vials
Both molecules are stocked in a 5 mg format, which makes the arithmetic directly comparable. A 5 mg vial reconstituted in 2 mL of bacteriostatic water gives 2.5 mg/mL. Converting to molarity: 2.5 mg/mL divided by 4409.07 g/mol is roughly 567 micromolar for cagrilintide, while the same 2.5 mg/mL of semaglutide at 4113.58 g/mol is roughly 608 micromolar. That 7% offset is invisible on a label and obvious in a fitted curve, so record both the mass concentration you prepared and the molar concentration you used. Working stocks for cell assays are usually diluted from this into assay buffer immediately before use rather than stored dilute, since dilute peptide solutions lose material to surfaces faster than concentrated ones.
Purity and identity checks
Request the lot-matched certificate of analysis for each and read three things: HPLC purity with a visible trace, a mass-spectrometric result matching the expected molecular weight — 4409.07 g/mol for cagrilintide and 4113.58 g/mol for semaglutide — and a lot number matching the vial. For cagrilintide add one check the incretin analogs do not need: confirm the material is the oxidised, disulfide-closed form rather than the reduced linear species, since the two differ by only 2 Da and behave very differently at the receptor. Counter-ion content and residual water mean the labelled mass overstates net peptide in both cases, so anchor comparative work to a measured concentration.
Regulatory framing
Cagrilintide and semaglutide are supplied for laboratory research use only. Semaglutide is the active molecule in approved prescription medicines and cagrilintide has been studied in investigational clinical programmes; the human evidence attaches to those regulated articles and to supervised clinical settings. Neither is offered here as a medicine, and neither is intended for human or veterinary use.